Penumbra (PEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, at company headquarters in Alameda, CA.
Shareholders are invited to vote on key proposals, including director elections, auditor ratification, and executive compensation.
Voting can be completed online, by mail, or in person at the meeting.
Voting matters and shareholder proposals
Election of three Class II director nominees to serve until the 2027 annual meeting: Arani Bose, M.D., Bridget O'Rourke, and Surbhi Sarna.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation as disclosed in the proxy statement.
Proxy holders authorized to vote on any other business that may arise at the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all three proposals, including director nominees and auditor ratification.
Latest events from Penumbra
- Q2 2026 revenue up 14.9% to $390M, net income $34.8M, $14.5B Boston Scientific merger announced.PEN
Q2 2026 - Q1 2026 revenue rose 15.6% to $374.8M; net income was $32.6M; merger pending.PEN
Q1 2026 - Annual meeting covers director elections, auditor ratification, and say-on-pay, with merger pending.PEN
Proxy filing - Shareholders to vote on Penumbra's $374/share cash or stock merger with Boston Scientific.PEN
Proxy filing - Double-digit revenue and profit growth in 2025, with strong U.S. product sales and improved margins.PEN
Q4 2025 - Mechanical thrombectomy proved superior to anticoagulation for intermediate high-risk PE, reshaping care.PEN
Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 - Q3 revenue up 11.1% to $301M, with 21.2% U.S. thrombectomy growth and margin expansion.PEN
Q3 2024 - Q2 revenue up 14.5% with strong thrombectomy growth, but guidance cut on global headwinds.PEN
Q2 2024 - CAVT innovation and strong share gains in VTE drive a 15-16% CAGR growth outlook.PEN
2024 Truist Securities MedTech Conference